Patents Represented by Attorney, Agent or Law Firm Micheline Gravelle
  • Patent number: 6596287
    Abstract: The present invention provides novel emulsion formulations which comprise oil bodies. The invention also provides a method for preparing the emulsions and the use of the emulsions in products for topical application to the skin. The products are very mild to the skin and may be easily formulated into a wide variety of personal care and dermatological products.
    Type: Grant
    Filed: October 24, 2001
    Date of Patent: July 22, 2003
    Assignee: SemiBioSys Genetics Inc.
    Inventors: Harm M. Deckers, Gijs van Rooijen, Joseph Boothe, Janis Goll, Maurice M. Moloney
  • Patent number: 6593132
    Abstract: The present invention provides a protein having an A chain of a ricin-like toxin, a B chain of a ricin-like toxin and a heterologous linker amino acid sequence, linking the A and B chains. The linker sequence contains a cleavage recognition site for a disease specific protease such as a cancer, fungal, viral or parasitic protease. The invention also relates to a nucleic acid molecule encoding the protein and to expression vectors incorporating the nucleic acid molecule. Also provided is a method of inhibiting or destroying mammalian cancer cells, cells infected with a virus, a fungus, or parasite, or parasites utilizing the nucleic acid molecules and proteins of the invention and pharmaceutical compositions for treating human cancer, viral infection, fungal infection, or parasitic infection.
    Type: Grant
    Filed: October 29, 1999
    Date of Patent: July 15, 2003
    Assignee: Twinstrand Therapeutics Inc.
    Inventor: Thor Borgford
  • Patent number: 6582710
    Abstract: The present invention provides novel emulsion formulations which comprise oil bodies. The invention also provides a method for preparing the emulsions and the use of the emulsions in products for topical application to the skin. The products are very mild to the skin and may be easily formulated into a wide variety of personal care and dermatological products.
    Type: Grant
    Filed: January 29, 2002
    Date of Patent: June 24, 2003
    Assignee: Sembiosys Genetics Inc.
    Inventors: Harm M. Deckers, Gijs van Rooijen, Joseph Boothe, Janis Goll, Maurice M. Moloney
  • Patent number: 6537812
    Abstract: The method for obtaining and expanding TcR&ggr;&dgr;+ T cells in culture is described. The method involves: 1) culturing cells from a sample containing TcR&ggr;&dgr;+ T cells or precursors thereof in a first culture medium comprising a T cell mitogen and at least two cytokines and 2) culturing the cells obtained in step 1) in a second culture medium comprising at least two cytolines. Preferably, the method comprises 1) culturing the cells in a first culture medium comprising (a) a T cell mitogen, (b) interleukin-2 and (c) interleukin-4, and 2) culturing the cells obtained in step 1) in a second culture medium comprising (i) interleukin-2 and (ii) interleukin-4 to obtain TcR&ggr;&dgr;+ T cells. The TcR&ggr;&dgr;+ T cells obtained by the method can be used in a variety of experimental, therapeutic and commercial applications.
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: March 25, 2003
    Assignee: Hemosol Inc.
    Inventors: David Nicholson Bell, Danna Lynn Skea, Phyllis Robin Hedge
  • Patent number: 6531125
    Abstract: The present invention provides a protein having an A chain of a ricin-like toxin, a B chain of a ricin-like toxin and a heterologous linker amino acid sequence, linking the A and B chains. The linker sequence contains a cleavage recognition site for a retroviral protease such as HIV or an HTLV protease. The invention also relates to a nucleic acid molecule encoding the protein and to expression vectors incorporating the nucleic acid molecule. Also provided is a method of inhibiting or destroying mammalian cells infected with a retrovirus utilizing the proteins of the invention; and pharmaceutical compositions for treating HIV infections and human T-cell leukemias involving HTLV.
    Type: Grant
    Filed: April 14, 2000
    Date of Patent: March 11, 2003
    Assignee: Twinstrand Therapeutics Inc.
    Inventor: Thor Borgford
  • Patent number: 6509453
    Abstract: A method for the separation of a target molecule from a mixture is described. The method employs oil bodies and their associated proteins as affinity matrices for the selective, non-covalent binding of desired target molecules. The oil body proteins may be genetically fused to a ligand having specificity for the desired target molecule. Native oil body proteins can also be used in conjunction with an oil body protein specific ligand such as an antibody or an oil body binding protein.
    Type: Grant
    Filed: August 27, 1999
    Date of Patent: January 21, 2003
    Assignee: SemBioSys Genetics Inc.
    Inventors: Maurice Moloney, Joseph Boothe, Gijs Van Rooijen
  • Patent number: 6491918
    Abstract: The present invention relates to antibody composition that are useful in preparing enriched cell preparations such as human hematopoietic progenitor cells and stem cells and non-hematopoietic tumor cells. The invention also relates to kits for carrying out the processes and to the cell preparations prepared by the processes.
    Type: Grant
    Filed: October 28, 1999
    Date of Patent: December 10, 2002
    Assignee: StemCell Technologies Inc.
    Inventors: Terry Thomas, Peter Lansdorp
  • Patent number: 6491917
    Abstract: The present invention relates to an antibody composition which contains antibodies specific for glycophorin A, CD2, CD3, CD14, CD15, CD16, CD19, CD24, CD56, CD66b and IgE antigens. A negative selection process is also provided for use on blood and bone marrow samples from a patient with chronic myeloid leukemia to recover cell preparations depleted of lineage committed cells. The invention also relates to kits for carrying out this process and to the cell preparations prepared by the process.
    Type: Grant
    Filed: July 30, 1999
    Date of Patent: December 10, 2002
    Assignee: StemCell Technologies Inc.
    Inventors: Terry E. Thomas, Connie J. Eaves
  • Patent number: 6482926
    Abstract: The present invention relates to antibody composition that are useful in preparing enriched cell preparations such as human hematopoietic progenitor cells and stem cells and non-hematopoietic tumor cells. The invention also relates to kits for carrying out the processes and to the cell preparations prepared by the processes.
    Type: Grant
    Filed: March 22, 2000
    Date of Patent: November 19, 2002
    Assignee: StemCell Technologies Inc.
    Inventors: Terry Thomas, Peter Lansdorp
  • Patent number: 6455494
    Abstract: The invention related to a GPI-anchored p97 and a soluble form of p97 and derivatives thereof and methods for preparing the same. Methods of using p97 in modulating iron transport, in the delivery of therapeutic agents, and in the treatment of conditions involving disturbances in iron metabolism are described. The treatment and diagnosis of Alzheimer's Disease in view of the finding that p97 and transferrin receptor are markers for microglial cells associated with senile plaques are also described.
    Type: Grant
    Filed: April 1, 1999
    Date of Patent: September 24, 2002
    Assignee: University of British Columbia
    Inventors: Wilfred A. Jefferies, Patrick L. McGeer, Sylvia Rothenberger, Michael R. Food, Tatsuo Yamada, Malcolm Kennard
  • Patent number: 6447990
    Abstract: An artificial test soil (ATS) for “simulated-use” testing and cleaning validation studies of medical devices (including narrow lumened flexible endoscopes and other difficult to clean medical devices) is described. In addition, a cleaning validation test kit is described for users of medical devices to determine if adequate cleaning/rinsing has been performed on the medical device. The ATS formulations are based on the “worst-case” types and amounts of physiological soil components present in material recovered from patient-used flexible narrow-lumened endoscopes used for colonoscopy, bronchoscopy and duodenoscopy, but is applicable to a wide range of medical devices that might encounter similar types of soil.
    Type: Grant
    Filed: May 25, 2001
    Date of Patent: September 10, 2002
    Assignee: University of Manitoba
    Inventor: Michelle J. Alfa
  • Patent number: 6448075
    Abstract: The present invention relates to methods for separating cells using immunorosettes. The method involves contacting a sample containing nucleated cells and red blood cells with an antibody composition which allows immunorosettes of the nucleated cells and the red blood cells to form. The antibody composition preferably contains bifunctional antibodies or tetrameric antibody complexes.
    Type: Grant
    Filed: May 26, 2000
    Date of Patent: September 10, 2002
    Assignee: StemCell Technologies Inc.
    Inventors: Terry E. Thomas, Carrie Peters, Peter Lansdorp
  • Patent number: 6444804
    Abstract: Novel nucleic acid molecules encoding proteins involved in the synthesis and assembly of core lipopolysaccharide in P. aeruginosa; and novel proteins encoded by the nucleic acid molecules are described. Methods are disclosed for detecting P.aeruginosa in a sample by determining the presence of the proteins or a nucleic acid molecule encoding the proteins in the sample.
    Type: Grant
    Filed: November 2, 1999
    Date of Patent: September 3, 2002
    Inventors: Joseph S. Lam, Teresa R. De Kievit, Lori L. Burrows, Andrew Walsh, Mauricia Matewish
  • Patent number: 6403089
    Abstract: Methods for mediating immune coagulation using novel antibodies and compounds are described. A protein Fgl2 having direct prothrombinase activity has been identified. Inhibitors of Fgl2 are useful in preventing and treating diseases which require a reduction in immune coagulation including bacterial and viral infections, allograft and xenograft rejection, glomerulonephritis, cancer, a number of gastrointestinal diseases and fetal loss.
    Type: Grant
    Filed: November 15, 1999
    Date of Patent: June 11, 2002
    Assignee: Transplantation Technologies Inc.
    Inventors: Gary Levy, David A. Clark
  • Patent number: 6372234
    Abstract: The present invention provide novel emulsion formulations which comprise oil bodies. The invention also provides a method for preparing the emulsions and the use of the emulsions in products for topical application to the skin. The products are very mild to the skin and may be easily formulated into a wide variety of personal care and dermatological products.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: April 16, 2002
    Assignee: SemBioSys Genetics Inc.
    Inventors: Harm M. Deckers, Gijs van Rooijen, Joseph Boothe, Janis Goll, Maurice M. Moloney
  • Patent number: 6361998
    Abstract: The present invention describes a serum-free medium that promotes the growth and differentiation of erythroid cells, cells that are highly transducible by a non-viral method and genes which increase the growth of erythroid cells and decrease their dependency on Epo. This invention can be used in the expansion of hematopoietic stem cells to produce cultures of erythroid cells as a source of erythroid-specific proteins such as hemoglobin. Hematopoietic stem cells are cultured ex vivo in a serum-free culture medium with the addition of IL-3, SCF and EPO. Cells transfected with the gene described in the present invention can be cultured in the serum-free culture medium with decreased dependency on Epo and other cytokines, thereby reducing the cost of the production of hemoglobin.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: March 26, 2002
    Assignee: Hemosol Inc.
    Inventors: David N. Bell, Kathryn Emma Matthews, Susan G. Mueller
  • Patent number: 6361770
    Abstract: A method of enhancing expression of MHC Class I molecules bearing endogenous peptides on the surface of a target cell expressing low or nondetectable levels of MHC Class I molecules and expressing low or nondetectable levels of TAP-1 and TAP-2 transporter proteins comprising: introducing into the target cell a nucleic acid molecule comprising a sequence encoding TAP-1 or TAP-2 under control of a suitable promoter; and expressing TAP-1 or TAP-2 in the target cell under suitable conditions, thereby enhancing processing and presentation of MHC Class I molecules bearing endogenous peptides.
    Type: Grant
    Filed: July 21, 1997
    Date of Patent: March 26, 2002
    Assignee: University of British Columbia
    Inventors: Wilfred A. Jefferies, Reinhard Gabathuler, Gregor S. D. Reid, Gerassimos Kolaitis
  • Patent number: 6342344
    Abstract: The present invention relates to an antibody composition which contains antibodies directed to murine leukocyte and murine erythroid cells. This composition is used in a novel negative selection process to enrich for human hematopoietic cells from a sample from human-murine chimeric mice. The invention also relates to kits for carrying out this process.
    Type: Grant
    Filed: July 30, 1999
    Date of Patent: January 29, 2002
    Assignee: StemCell Technologies Inc.
    Inventors: Terry E. Thomas, Connie J. Eaves
  • Patent number: 6338851
    Abstract: Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of an OX-2 protein or a nucleic acid encoding an OX-2 protein. The methods are useful in preventing graft rejection, fetal loss, autoimmune disease, and allergies. Methods and compositions for preventing immune suppression are also disclosed. The methods involve administering an effective amount of an agent that inhibits OX-2.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: January 15, 2002
    Assignee: Transplantation Technologies Inc.
    Inventor: Reginald M. Gorczynski
  • Patent number: 6333303
    Abstract: The present invention provides a protein having an A chain of a ricin-like toxin, a B chain of a ricin-like toxin and a heterologous linker amino acid sequence, linking the A and B chains. The linker sequence contains a cleavage recognition site for a retroviral protease. The invention also relates to a nucleic acid molecule encoding the protein and to expression vectors incorporating the nucleic acid molecule. Also provided is a method of inhibiting or destroying mammalian cells infected with a retrovirus utilizing the proteins of the invention and pharmaceutical compositions for treating HIV infection.
    Type: Grant
    Filed: March 2, 1999
    Date of Patent: December 25, 2001
    Assignee: Twinstrand Therapeutics Inc.
    Inventor: Thor Borgford